Health Economics›Uveal melanoma›Metastatic or unresectable disease all lines of therapy

Metastatic or unresectable disease all lines of therapy

Uveal melanoma · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Selumetinib monotherapy Variant #01	—	R 308 264	28d	3.7 mo	—	5	R 1 541 319 PFS proxy	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	~11.5 mo	~71.9 mo	~9	~R 707 538 PFS proxy · indirect	7
Temozolomide monotherapy Variant #13	—	R 8 153	28d	1.6 mo	—	2	R 16 306 PFS proxy	1
Dacarbazine monotherapy Variant #01	—	R 2 094	21d	1.6 mo	—	3	R 6 282 PFS proxy	1
Fotemustine monotherapy Variant #01 Partial	—	—	56d	—	13.8 mo	—	—	1
TILs and High-dose Interleukin-2 Variant #01 Partial	—	—	—	—	—	—	—	—
TACE monotherapy Variant #01 Partial	—	—	—	~8.2 mo	~26.1 mo	—	—	9

7 of 7 regimens shown